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Summary: A fluorescence polarisation immunoassay for quantitating serum concentrations of valproic acid
was developed and validated. Its low molecular weight and lack of structural features caused difficulties in
producing suitable antibodies. However, success was achieved using 2-propyl-6-aminohexanoic acid to make
the fluorescein-labelled drug and two immunogens, the first using glutaraldehyde to link the drug derivative
to keyhole limpet haemocyanin, and the second by carbodiimide activation of cellulose hydroxyl groups and
coupling them to the drug derivative and killed Mycobacteria. It was found that both immunogens produced
a good antibody response in sheep. The antibodies were highly specific and the assay results correlated well
with an in-house gas-liquid Chromatographie method.
Introduction
During recent years, valproic acid has become a first-
choice drug in the treatment of most types of epilepsy.
There is increasing interest in its quantitative meas-
urement in plasma or serum for the detection of poor
compliance and because of the great individual dif-
ferences in dosage requirements to achieve therapeutic
concentrations (1, 2). Various assay methods have
been introduced including gas-liquid chrornatography
(3), high-performance liquid chromatography (4) and
immunoassays (5). Enzymeimmunoassays and fluo-
rescence polarisation immunoassays are now the most
widely used in therapeutic drug monitoring due to
their simplicity, and the availability of automated or
semiautomated instruments and commercial kits (6).
In addition to their speed and high sample throughput
these methods are reliable and specific and the results
obtained correlate well with Chromatographie meth-
ods (7).
It proved difficult to raise suitable antibodies against
valproic acid because of its small size and structural
simplicity. Coupling the drug directly to keyhole lim-
pet haemocyanin through its free carboxyl group, or
coupling dipropyl malonic acid (2-carboxy valproic
acid) to the carrier protein proved unsuccessful; both
resulted in the production of ovine antibodies able to
bind the fluorescein-labelled derivative prepared
through the same functional group, but not the un-
labelled drug. However, a suitable antibody response
is produced in sheep immunised with an immunogen
prepared by coupling the hydrocarbon chain of the
molecule, via a suitable functional group, to keyhole
limpet haemocyanin, and the resulting antisera used
with a fluorescein-labelled derivative prepared
through the same route. These reagents were em-
ployed to develop the present single-reagent fluores-
cence polarisation immunoassay (FPIA) for the direct
determination of valproic acid in serum.
Materials and Methods
Reagents
Sodium valproate was a gift from Reckitt and Colman, Kings-
ton-upon-Hull, U. K. Valproate metabolites were gifts from Dr.
H. Schafer, Desitin-Werk Carl Klinke GmbH Hamburg,
F. R. G. and from Sanofi UK Ltd, Manchester, U. K. Fluores-
cein isothiocyanate isomer l (FITC), Sigmacell type 20, and
most chemicals used in synthesis and cross-reactivity experi-
ments were obtained from Sigma, Poole. Dorset. U. K.: keyhole
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limpet haemocyanin from Calbiochem-Behring, San Diego, CA
92112, U.S.A.; silica gel thin-layer chromatography (TLC)
plates (type PLK5F) from Whatman, Maidstone, Kent, U. K.;
triethylamine from Koch-Light, Colnbrook, Bucks, U. K.; Tri-
ton X-100 surfactant, sodium azide, sodium lauryl sulphate and
all organic solvents ("Analar" grade) from BDH Chemicals,
Poole, Dorset, U. K.; and pooled normal human serum from
ILS, London EC1, U. K. Other drugs employed in the specific-
ity studies were donated by their respective U. K. distributors.
Assay standards
A 1 g/1 solution of valproic acid in methanol was prepared and
added to drug-free pooled normal human serum to obtain the















Serum samples from patients receiving valproic acid, with or
without other antiepileptic drugs, were obtained and assayed
by a gas-liquid Chromatographie method (8).
Fig. 1. Structural formulae of (a) valproic acid, (b) diprppyl
malonic acid, and (c) 2-propyl-6-amino hexanoic acid.
Diluent buf fe r
Sodium phosphate buffer (100 mmol/1, pH 7.5) containing per
litre, 1.0 mg sodium lauryl sulphate, 2.2 mg Triton X-100 and
l g of sodium azide as an antibacterial agent.
Assay tubes
Disposable 50 10 mm round glass cuvettes (no. 9518), from
Abbott Diagnostic Division, Basingstoke, Hampshire, U. K.
Valproate immunogen I
2-Propyl·6-aminohexanoic acid (50 mg, 0.3 mmol) was reacted
with 1 ml of 50 g/1 glutaraldehyde (0.6 mmol) in 1 ml of 1 mol/l
acetate büffer pH 7.0. After 5 min of continuous mixing, this
was added to a solution of 60 mg keyhole limpet haemocyanin
in 5 mi acetate buffer and stirred for 30 min. Then a solution
of 100 mg sodium borohydride in 2ml distilled water was
added; the reaction mixture stirred for 15 min; transferred to a
dialysis bag and dialysed for 3 days against three changes of 5
litres of phosphate buffered saline (50 mmol/1, pH 7.4). When
lyophilised, it yielded 76 mg of the conjugate.
Polarisation fluorometer
A Model 4000 polarisation fluorometer (SLM Instruments,
Urbana, IL 61801) was employed, as described previously (8),
except that the sample compartment was fitted with an adaptor
to accept the cylindrical cuvettes.
Preparation procedures
2-Propyl-6-aminohexanoic acid
Sodium hydride (0.43 g, 10.7 mmol) was dissolved in 30 ml of
dry dimethyl formamide and reacted with 2 ml (9.7 mmol) of
diethylpropylmalonate. After 30 min with continuous stirring,
2.7 g (9.7 mmol) of N-(4-bromobutyl) phthalimide was added
and refluxed for 1.5 h. The reaction mixture was diluted with
ether, washed several times with water, dried over magnesium
sulphate and the solvent evaporated under reduced pressure to
yield a yellow oil. This was purified by flash column chroma-
tography (petroleum ether/diethyl ether, 2 4-1 by vol) to obtain
3.6 g (91% yield) of a white solid diethyl-(4-N-butyl phthal-
imide)propyl malonate. This diester (0.85 g, 2.1 mmol) and 0.5
ml (10 mmol) of hydrazine were then dissolved in 30 ml meth-
anol and refluxed for 4h. After removing the solvent, the
residue was dissolved in l mol/l HC1, washed with chloroform,
made alkaline with 2 mol/l NaOH and extracted with chloro-
form. The organic phase was washed with water, dried over
magnesium sulphate and the solvent evaporated under vacuum
to yield an oil which was dissolved in 15 ml of 6 mol/l HC1 and
refluxed overnight. The reaction mixture was neutralised, the
water evaporated and the residue extracted with methanol.
Upon filtration and removal of the solvent, 0.23 g of a white
solid (2-propyl-6-aminohexanoic acid) was obtained (fig. 1).
Valproate immunogen II
Carbonylimidazole (30 mg) was added to a suspension of Sig-
macell Type 20 cellulose in 2 ml of dry acetone and stirred for
l h at room temperature. Then a solution of 2-propyl·6r·ami-
nohexanoic acid (50 mg, 0.3 mmol) and triethylamine (50 ul)
iri~l ml of acetone was added. After stirring for 1 h, 30 mg of
a suspension of killed Mycobäcteria in water was added. The
reaction mixture was stirred overnight, dialysed as above and
lyophilised to yield 146 mg of the conjugate.
Fluorescein tracer
Ten mg (0.06 mmol) of 2-propyl-6-aminohexanoic acid and
10 mg (0.03 mmol) of fluorescein isothiocyanate isomer^l were
dissolved in 2 ml methanol containing 1 ml/1 of triethylamine.
After stirring for 2 h, in the dark, at ambient temperature, the
solution was acidified with l mol/l HC1 and then filtered. The
precipitate obtained was dissolved in methanol and purified by
thin-layer chromatqgraphy, using methylene chloride/methanol
(1 4· 1 by vol) to separate a major band (Rf 0.3). The band was
scraped from the plate, extracted with methanol and stored at
—20 °C. The concentration of the fluorescein tracer was esti-
mated spectrophotometrically as described previously (10).
Anti-valproic add anti-sera
Three ewes were immunised with immunogen 1 (no. 101, 102,
and 103) and an additional 3 ewes with immunogen II (no. 14,
15, 16) according to a protocol described e^ewhere (10).
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Procedures
Gas-liquid chromatography procedures
A Pye Unicam series 304 instrument linked to a Hewlett Pack-
ard 3380A integrator was used for routine determination of
valproic acid in serum samples following an established method
(8). Briefly, each serum sample was acidified with 1 mol/1 HC1
and added to a glass tube containing benzyl alcohol as internal
standard. Then the sample was extracted into 1 ml chloroform
of which 5 μΐ was injected directly onto a column packed with
100 g/1 diethylglycol succinate on Chromosorb W.H.P. 100/
120 mesh.
Fluorescence polarisation immunoassay (FPIA) procedures
Premixed reagent: A solution of fluorescein labelled valproate
in assay buffer was prepared at a concentration of 30 nmol/1.
To this was added anti-valproate anti-serum (pre-diluted 100-
fold) in the ratio 2:1. The reagent was then stored at 4 °C in
the dark until required.
Assay protocol: Assays were performed at room temperature in
duplicate. To 25 μΐ of diluted serum standard or sample (pre-
diluted 50-fold in diluent buffer) was added 1.5 ml of the
premixed reagent in the glass cuvette. The cuvettes were vortex




Characterisation of the valproate immuno-
gens
Immunogens I and II were hydrolysed by refluxing
with 10 ml of dilute HC1 for 1 h. Upon diluting the
product in the assay buffer and measuring the con-
centration of valproate by the present assay, a ratio
of "valproic acid equivalent" to the carrier was ob-
tained: 0.7 mmol/g (2300:1 in molar terms) for
immunogen I and 0.03 mmol/g for immunogen II.
Anti-valproate anti^sera
All sheep produced antibodies that bound valproic
acid but the antisera varied significantly in their litres.
The immunoglobulin fraction of each serum and of
a non-immunised sheep serum were obtained by con-
ventional sodium sulphate precipitation (11) and dou-
bly diluted in diluent buffer. Antibody dilution curves
were constructed by adding 1 ml aliquots of these
dilutions to 0.5 ml of the fluorescein tracer (30
nmol/1), measuring fluorescence polarisation and
making a background correction. Figure 2 shows such
curves for the most responsive sheep to each immu-
nogen (no. 102 and 14) and for a non-immunised











Fig. 2. Dilution curves of the immunoglobulin fractions of anti-
valproic acid antisera obtained from
the second bleed of sheep 102 (o),
the eighth bleed of sheep G14 (o) and
a non-immunised sheep serum (Δ).
The polarisation of fluorescence (P) is defined as:
In - Ii '
where
I(| = intensity of the fluorescence when the exciting
light is vertically polarised (parallel to the direc-
tion of the electric vector of the exciting wave)
Ix = intensity of the fluorescence when the exciting
light is horizontally polarised (perpendicular to
the direction of the electric vector of the exciting
wave)
As a quotient, Ρ has the unit 1 (one, dimension-less).
Optimisation of assay conditions
The presence of albumin and other serum proteins
increased the fluorescence polarisation signal due to
non-specific binding with the fluorescein tracer. This
was abolished by incorporating 1.0 mg/1 of sodium
lauryl sulphate as a blocking agent in assay diluent
buffer. Triton X-100 was added in equimolar concen-
tration (2.2 mg/1) in the assay b ffer to overcome the




The association of the fluorescein tracer with the
valproate antibodies was investigated by obtaining
serial polarisation readings after adding 0.5 ml of
tracer (30 nmol/1) to 1 ml of the antiserum (diluted
100-fold), which were plotted against time on linear
paper. The polarisation readings increased rapidly and
reached a plateau within 45 s.
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Dissociation kinetics
The rate of dissociation was investigated as previously
described (6). Two populations of antibody were
found, one with a polarisation half life of about 57 s,
and the other, a faster dissociating antibody, with a
half-life of about 24 s. Both constitute a substantial
proportion of the total antibody populations.
Incubation time
Each standard was assayed and polarisation readings
taken at timed intervals. The assay reached equilib-
rium after 10 min and the polarisation readings were
stable for at least 45 min.
Standard curve
A typical standard curve (fig. 3) was obtained using
25 μΐ of buffer or serum standard (prediluted 50-fold)




The sensitivity of the assay was determined by the
Rodbard method (13). The minimal detectable con-
centration of valproic acid was 1.9 mg/1 and the
minimal detectable dose was 0.95 ng per tube.
Imprecision
Three selected samples of patients' sera were each
assayed ten times in one assay, and gave mean results
of 37, 90, and 132 mg valproic acid per litre with CVs
of 3.7%, 3.5% and 3.8% respectively. The same sam-
ples were assayed on ten separate occasions and gave
between-assay CVs of 5.9%, 4.1%, and 3.1% respec-
tively. A precision profile was calculated using the
Edinburgh immunoassay program (14) from the data
collected from a standard curve and the simultaneous
assay of 50 patients' samples. Within the boundaries
of the standard curve the CVs were all below 10%
(fig. 4).
Analytical recovery
Valproic acid was added at concentrations of 10, 20
and 50 mg/1 to four patients' samples containing
valproic acid in concentrations ranging from 0 to 125
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Fig. 3. Standard curves for valproic acid obtained by fluores^·
cence polarisation (o) and from the Logit^-Log trans-·
formation (o).








The standard curve for valproic acid exhibited good
linearity (fig. 3). When a patient's seniin containing
a high concentration of valproic acid (130 mg/1) was
diluted 2-, 4-, 8-, and 16-fold in diluent buffer, the
values obtained were linear and parallel to the normal
standard curve.
The results obtained from a typical standard curve
were processed by the Logit-Log program (15) con-
verting polarisation readings to B/B0 values. A
straight line was obtained which was parallel to the
normal standard curve (fig. 3). ; *
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Specificity
Antibody specificity
To assess the specificity of the anti-valproate antibod-
ies, the following chemicals, sharing some structural
similarity to valproic acid, were tested for their cross-
reactivity at a concentration of 1 g/1; ethanoic acid,
propanoic acid, butanoic acid, pentanoic acid, hex-
anoic acid, heptanoic acid, norvaline, valine, amino-
rt-valeric acid, ornithine, valeric acid ethyl ester and
benzoyl amino-rt-valeric acid. The aliphatic carboxylic
acids did cross-react, but not significantly — all less
than 2%. All other analytes showed zero cross-reac-
tivity, demonstrating the high specificity of the anti-
bodies produced.
inaccuracy in the assay of patients' samples. Other
antiepileptic drugs and their major metabolites
showed no cross-reaction when tested at concentra-
tions up to 1 g/1.
Accelerated stability study
A bulk (50 ml) of the premixed reagent was prepared
and after overnight incubation, a standard curve was
obtained. The reagent was then stored in the dark at
37 °C for a week, after which a comparable standard
curve was obtained, indicating that the single reagent
should be stable for a year at 4 °C (18).
Clinical specificity
The cross-reactivity of the main metabolites of val-
proate (16) were determined at a concentration of
1 g/1, relative to valproic acid. Those which cross-
reacted significantly at this level were further assessed
by Abraham's method (17). The results are shown in
table 1. None cross-reacted to an extent likely to cause
Correlation with gas-liquid chromatography
method
Results of the assay of 46 patients' serum samples by
this assay (y) and by the Chromatographie technique
(x) were related by the regression line y = 1 .Ox + 2.9
(r = 0.99) which was calculated assuming that the
two methods have equal precision characteristics (19).
Tab. 1. Cross-reactivity of valproic acid metabolites
Compound % Cross- % Cross-
reactivity reactivity




































We describe another "single-reagent FPIA" utilizing
the short dissociation half-lives of most hap-
ten: antibody complexes (6, 18). For such assays to
be feasible, one requires antiserum which contains a
substantial population of fast dissociating antibodies.
In spite of the initial difficulties encountered in raising
antibodies to such a small molecule, we were even-
tually successful in producing an antiserum which
contains a substantial proportion of fast dissociating
antibodies. These antibodies consist of two major
populations with polarisation half-lives of 24 s and
57 s, which have allowed us to develop the present
single-reagent FPIA for valproic acid.
The additional advantage of such assays is the long-
term stability of the premixed reagent as shown by
the accelerated stability study. The premixed reagent
was stable and gave comparable results when stored
at 37 °C for 1 week which implies one year's stability
at 4 °C (18).
In raising antisera to valproic acid two immunogens
were prepared by coupling 2-propyl-6-aminohexanoic
acid to two different carrier molecules. The high val-
proate/keyhole limpet haemocyanin incorporation ra-
tio in immunogeh I may have resulted in the greater
antibody response in the immunised sheep, as com-
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pared with the second immunogen (valproate/Sig-
maczl\-Mycobacleria conjugate).
The specificity studies show that highly specific anti-
bodies were produced, with, as expected, optimum
selectivity for the carboxylic acid group of valproic
acid. The introduction of a hydroxyl or a oxo group
close to the carboxylic acid grouping prevents anti-
body binding, but a hydroxyl group further along the
molecule is less effective and 5-hydroxy valproic acid
therefore shows greater cross-reactivity than its 4-
hydroxy and 3-hydroxy counterparts. The presence
of an additional carboxyl group in 2-H-propyl glutaric
acid, although at the far end of the molecule, pre-
vented antibody binding presumably by modifying
the polarity, electron density, and the effective charges
of the molecule, thereby interferring with the forces
involved in antigen-antibody binding.
The only other cross-reacting compounds were 2-en
and 4-en valproic acid suggesting that some antibody
populations cannot distinguish between unsaturated
and saturated compounds. The 4-en compound is the
more immunoreactive probably because of the relative
positions of the carbon-carbon doublp bonds. How-
ever these cross-reactants will not interfere with the
assay of patients' samples since the plasma concen-
trations of all the metabolites are considerably lower
than those of the parent drug (16). This is shown by
the correlation coefficient (r) of 0.99 obtained when
the results of the immunoassay are compared with
those of the gas-chromatography method.
All other reliability criteria of the assay are satisfac-
tory and the small volume (0.5 μΐ) required provides
another advantage when limited sample volumes are
available especially in paediatric practice.
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